Title
In vitro and in vivo antileishmanial activity of β-acetyl-digitoxin, a cardenolide of Digitalis lanata potentially useful to treat visceral leishmaniasis
Date Issued
01 January 2021
Access level
open access
Resource Type
journal article
Author(s)
Freitas C.S.
Lage D.P.
Oliveira-Da-Silva J.A.
Costa R.R.
Mendonça D.V.C.
Martins V.T.
Reis T.A.R.
Antinarelli L.M.R.
Machado A.S.
Tavares G.S.V.
Ramos F.F.
Brito R.C.F.
Ludolf F.
Roatt B.M.
Ramos G.S.
Munkert J.
Ottoni F.M.
Campana P.R.V.
Duarte M.C.
Gonçalves D.U.
Coimbra E.S.
Braga F.C.
Pádua R.M.
Coelho E.A.F.
Publisher(s)
EDP Sciences
Abstract
Current treatments of visceral leishmaniasis face limitations due to drug side effects and/or high cost, along with the emergence of parasite resistance. Novel and low-cost antileishmanial agents are therefore required. We report herein the antileishmanial activity of β-acetyl-digitoxin (b-AD), a cardenolide isolated from Digitalis lanata leaves, assayed in vitro and in vivo against Leishmania infantum. Results showed direct action of b-AD against parasites, as well as efficacy for the treatment of Leishmania-infected macrophages. In vivo experiments using b-AD-containing Pluronic® F127 polymeric micelles (b-AD/Mic) to treat L. infantum-infected mice showed that this composition reduced the parasite load in distinct organs in more significant levels. It also induced the development of anti-parasite Th1-type immunity, attested by high levels of IFN-γ, IL-12, TNF-α, GM-CSF, nitrite and specific IgG2a antibodies, in addition to low IL-4 and IL-10 contents, along with higher IFN-γ-producing CD4+ and CD8+ T-cell frequency. Furthermore, low toxicity was found in the organs of the treated animals. Comparing the therapeutic effect between the treatments, b-AD/Mic was the most effective in protecting animals against infection, when compared to the other groups including miltefosine used as a drug control. Data found 15 days after treatment were similar to those obtained one day post-therapy. In conclusion, the results obtained suggest that b-AD/Mic is a promising antileishmanial agent and deserves further studies to investigate its potential to treat visceral leishmaniasis.
Volume
28
Language
English
OCDE Knowledge area
Inmunología Parasitología Farmacología, Farmacia
Scopus EID
2-s2.0-85104268221
PubMed ID
Source
Parasite
Resource of which it is part
Parasite
ISSN of the container
1252607X
Sponsor(s)
Funding text 1 This work was supported by grant MR/R005850/1 from the Medical Research Council (VAccine deveLopment for complex Intracellular neglecteD pAThogEns - VALIDATE), UK, and grant APQ-408675/2018-7 from the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq). Funding text 2 Acknowledgements. This work was supported by grant MR/ R005850/1 from the Medical Research Council (VAccine deveLopment for complex Intracellular neglecteD pAThogEns – VALIDATE), UK, and grant APQ-408675/2018-7 from the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brazil. The authors also thank the Brazilian agencies Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), CNPq and the Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG) for the student scholarships. The authors would also like to thank Professor Wolfgang Kreis (Universität Erlangen-Nürn-berg – Germany) for kindly providing a sample of β-acetyldigitoxin.
Sources of information: Directorio de Producción Científica Scopus